A Clinical Trial Company With A Purpose

  • Internal database and clinician private practices

    Our pharmaceutical and CRO partners are so important to us and we accomplish a lot together. We understand what it means to bring a clinical trial from site activation to study closeout while providing clean and timely data in between. The majority of our patients come from our physicians' private practice databases.

  • Safety & PI oversight

    Our team understands research. With dedicated full time study coordinators, and Investigators with their own built-in private practices onsite, YCT brings a highly sought after diverse pool of research-naive patients, and strong safety oversight to the studies we undertake.

  • Site Metrics and Data Driven

    With e-source and e-regulatory capabilities, electronic health records (certified copies available), combined with our GDPR e-storage of staff records, YCT is fully digital and prepared for the opportunities these capabilities will bring to our community of clinicians and patients.

  • Study Coordinators

    The study coordinator is the backbone of any clinical research project. Not only are our coordinators amongst the most experienced in the industry, but they understand the importance of screening and enrolling appropriate study participants. Two of our co-founders also founded and continue to manage The CRC Academy, one of the most reputable CRC online training programs in the industry.

Built for Sponsors: Our Numbers, Defined

We reduce enrollment and start-up risk in Phase II-IV trials by combining physician-practice access to a research-naive, majority-Hispanic patient population with fully digital site operations. Every number below comes directly from our CRIO (CTMS/eSource/eReg) system. Data period: through June 2026, refreshed quarterly. Sponsor names and protocol identifiers are intentionally withheld on this public page and shared under CDA.

Active Portfolio (source: CRIO, June 2026)

  • 16 studies in the active portfolio: 5 enrolling, 2 in start-up, 4 in maintenance/follow-up, 5 in close-out

  • 12 distinct sponsors, including 7 of the top-20 global pharmaceutical companies; 7 of our 16 studies are repeat-sponsor awards

  • Phase II-IV experience across cardiometabolic (type 2 diabetes, obesity, hypertension, heart failure, atrial fibrillation), respiratory (COPD), CNS/psychiatry (major depressive disorder, bipolar disorder), musculoskeletal (osteoarthritis), and dermatology (plaque psoriasis)

  • 260+ screening encounters and 840+ completed study visits logged in CRIO

  • 780+ pre-screened candidates tagged to active protocols in our CRIO recruitment database, in addition to our physicians’ private-practice populations

  • Central IRB: Advarra (CIRBI). eReg posture as of June 2026: zero expiring documents, zero missing training certifications, zero outstanding signature actions

How We Recruit: A System, Not A Hope

  1. Identification: CRIO recruitment database, our physicians’ private-practice records, and IRB-approved bilingual community outreach (see our Community Videos page)

  2. Pre-screen: coordinator review against protocol inclusion/exclusion criteria, documented in CRIO eSource

  3. Outreach: phone and text in English or Spanish using IRB-approved materials, with every attempt logged

  4. Scheduling: screening visits booked directly in CRIO scheduling

  5. No-show reduction: reminder outreach plus small-city geography that keeps travel burden low

  6. Retention: named-coordinator continuity from consent through close-out, with Spanish-language support at every visit

Our Enrollment Realism Policy

We do not commit to a specific enrollment number until we have reviewed the final protocol’s inclusion/exclusion criteria against our patient population. Initial expressions of interest reflect estimated eligibility; final commitments come after I/E review.

Representative Enrollment, By Design

  • Yuma County: 200,000+ residents, roughly two-thirds Hispanic or Latino (U.S. Census), historically underserved by clinical research

  • Bilingual operations end-to-end: consent, study visits, and follow-up conducted in English or Spanish

  • Largely research-naive patients drawn from our investigators’ own practices rather than professional study-subject pools

  • 2.5-hour drive from Phoenix or San Diego, plus an international airport, for regional and national CRAs

Technology Stack: A List, Not Adjectives

  • CTMS / eSource / eReg: CRIO, deployed site-wide

  • EHR: certified copies available for monitoring and audit

  • Central IRB workflow: Advarra CIRBI

  • Sponsor platforms onboarded in the last 24 months include Veeva Vault, conneXion, InvestigatorSpace, and ProofPilot

  • eConsent and decentralized visit components supported per protocol

  • Task board and staff collaboration: Coordinare

  • Participant ad placement and outreach: PatientACE

  • AI-enabled EHR mining per study: Inato

  • Fetch-and-fill data entry: Gleam

Metrics We Are Baselining Now

In line with ICH E6(R3) risk-proportionate quality management, we publish only metrics with defined denominators and time windows. Cycle-time medians (CDA, CTA, budget, IRB submission to approval), query aging, and protocol-deviation rates per subject are being formalized in our quarterly metric dictionary, implementing Q3 2026. If we do not track a number yet, we say so rather than estimate it.

What We Share Under CDA

Protocol-level enrollment and retention performance with defined denominators, screen-fail rates by indication, study references, and our full sponsor-ready site profile. Standard start-up documents (CDA template, rate card, W-9, insurance, banking) are ready at CDA stage. Contact dan@yumaclinicaltrials.com to request the current profile.